Cost-effectiveness of FDG-PET

Estudo de Custo-efetividade Para o Sistema único de Saúde - SUS Sobre o Exame de Metabolismo de Glicose Marcada Com Flúor-18 Pela Tomografia de emissão de pósitron-PET

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01438164

Enrollment

500

Registered

2011-09-21

Start date

2005-06-30

Completion date

2011-09-30

Last updated

2011-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncologic Patients

Keywords

FDG-PET, cancer, staging, Evaluate the cost impact in the evaluation of oncologic patients.

Brief summary

Evaluation of cost-effectiveness of FDG-PET for the public health system in Brazil.

Detailed description

To provide detailed information about cost and effectiveness of FDG-PET in multiple oncological diseases, such as Lymphoma, lung cancer and esophageal cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

13 Years to No maximum

Healthy volunteers

Inclusion criteria

* Cancer

Exclusion criteria

* Other malignancy * Uncontrolled Diabetes * Pregnancy

Outcome results